TREATMENT
Re-challenging BRAF V600E tumors with encorafenib, cetuximab, and nivolumab shows success — Clinical Colorectal Cancer
A case report from the AGMT mCRC Registry documented successful re-challenge with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch-repair-proficient (pMMR) metastatic colorectal cancer. This case suggests that adding immunotherapy to targeted therapy may restore sensitivity even after prior progression.
What this means
If your tumor has a BRAF V600E mutation and you've already progressed on encorafenib and cetuximab, this case report suggests that re-challenging with the same drugs plus nivolumab may be worth discussing with your oncologist, even if your tumor is not MSI-H.